AtriCure Updates FY 2026 Earnings Guidance

Medical device company raises revenue and earnings projections for the coming fiscal year.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

AtriCure, Inc., a medical device company focused on treatments for atrial fibrillation, has updated its financial guidance for fiscal year 2026. The company provided an earnings per share (EPS) range of $0.090 to $0.150, up from the previous consensus estimate of -$0.030. AtriCure also forecasted revenue between $600 million and $610 million, compared to the prior consensus of $604.3 million.

Why it matters

AtriCure's updated guidance suggests the company is seeing stronger than expected growth in its core business of surgical ablation devices used to treat atrial fibrillation. This indicates the market demand for the company's innovative therapies remains robust, which is positive news for investors and the long-term outlook of the business.

The details

AtriCure, headquartered in Mason, Ohio, develops and markets medical devices focused on treating atrial fibrillation, a common heart rhythm disorder. The company's key products include the Synergy Surgical Ablation System, which uses radiofrequency energy for minimally invasive procedures, and the cryoICE Cryoablation System, which employs freezing techniques. The updated FY 2026 guidance suggests the company is experiencing solid growth in sales and profitability as it continues to expand the adoption of its specialized cardiac ablation solutions.

  • AtriCure provided the updated FY 2026 guidance on Tuesday, March 4, 2026.

The players

AtriCure, Inc.

A medical device company focused on developing and marketing innovative therapies to treat atrial fibrillation and related cardiac conditions.

Got photos? Submit your photos here. ›

The takeaway

AtriCure's raised earnings and revenue outlook for fiscal year 2026 signals the company's cardiac ablation technologies continue to gain traction in the market, underscoring the strong demand for its minimally invasive treatment solutions for atrial fibrillation.